Exchange & Returns Information
Review Details
(33)
| Drug Type | Original |
|---|---|
| Active Ingredient | TIRZEPATIDE |
| Strength | 2.5MG |
| Manufacturer | ELI LILLY AND COMPANY |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 PEN | $ 208.00 | $ 208.00 |
$ 174.72
Apply MOUN26 (-16%)
You save $ 33.28
|
||
| 2 BOXES - 2 PENS | $ 154.50 |
26% $ 416.00
$ 309.00
|
$ 259.56
Apply MOUN26 (-16%)
You save $ 49.44
|
||
| ★ Best Value 3 BOXES - 3 PENS | $ 146.33 |
30% $ 624.00
$ 439.00
|
$ 368.76
Apply MOUN26 (-16%)
You save $ 70.24
|
Reference information will be available soon.
Mounjaro 2.5mg is the initiation dose of tirzepatide, a groundbreaking dual incretin receptor agonist that targets both GLP‑1 and GIP pathways. Designed as a once-weekly subcutaneous injection, it is FDA-approved for the treatment of type 2 diabetes in adults and delivers robust glycemic control by enhancing insulin secretion, suppressing glucagon release, and delaying gastric emptying. The dual receptor targeting enables broader metabolic effects compared to GLP-1 monotherapy. Although significant weight reduction has been observed in clinical studies, Mounjaro is not approved for obesity treatment; its role in weight loss is considered secondary. Notably, emerging research suggests its potential to reduce the risk of progression from prediabetes, improve outcomes in patients with obesity-related obstructive sleep apnea (OSA), and possibly modulate long-term risks associated with metabolic diseases, including certain cancers. The 2.5mg dose is intended strictly for treatment initiation and is not meant for long-term maintenance.
- DIABETES (GLP-1 Receptor Agonists) > Indicated for adults with type 2 diabetes mellitus to improve blood sugar control. Mounjaro provides superior HbA1c reduction compared to GLP‑1 receptor agonists alone, and is typically initiated at 2.5mg to assess tolerability before dose escalation. The drug can be used alone or in combination with metformin, SGLT2 inhibitors, or basal insulin. - DIET (Metabolic Weight Control) > Though not approved as a weight-loss medication, tirzepatide has demonstrated significant reductions in body weight as a secondary benefit. The appetite-suppressing and gastric emptying-delaying effects contribute to fat mass reduction. Long-term weight management studies have positioned tirzepatide as a potential future standard for metabolic syndrome interventions. - LIFESTYLE-RELATED DISEASES (Obstructive Sleep Apnea – off-label) > Weight reduction via tirzepatide therapy may contribute to improvement in obstructive sleep apnea symptoms in patients with comorbid obesity. Although Mounjaro is not approved for OSA, similar indications are found in the higher-dose Zepbound. - AntiCancer Drugs (Others – metabolic-linked cancer modulation) > Ongoing studies suggest that tirzepatide-induced metabolic improvements may lower risks for obesity-related cancers such as breast cancer. While these findings are preliminary, they reflect a growing interest in GLP‑1/GIP agonists as long-term modulators of chronic disease burden.
Tirzepatide acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and significantly slows gastric emptying. GIP activation is believed to amplify insulinotropic activity and reduce food intake synergistically with GLP-1. This comprehensive metabolic engagement leads to significant HbA1c reduction and consistent body weight loss. The therapy also supports cardiovascular benefits and is under investigation for its neuroprotective and anticancer potential. Compared to GLP-1 monotherapy, tirzepatide demonstrates superior efficacy in glucose and weight parameters.
→ Weekly Subcutaneous Injection (Type 2 Diabetes Indication): - Week 1–4: 2.5 mg SC once weekly *(Initiation dose – this product)* - Week 5+: increase to 5 mg SC once weekly - May further escalate by 2.5 mg increments every 4 weeks as needed: - 7.5 mg → 10 mg → 12.5 mg → up to 15 mg weekly → Max Dose: 15 mg SC per week → Maintenance Dose: 5–15 mg SC weekly depending on patient response → Administration Notes: - Inject subcutaneously into abdomen, thigh, or upper arm - Administer on the same day each week, with or without meals - If missed, administer within 96 hours; skip if more than 4 days have passed → Drug Interactions / Adjustments: - May be used with metformin, SGLT2 inhibitors, or insulin - Reduce sulfonylurea or insulin doses at initiation to prevent hypoglycemia → Special Considerations: - Not for use in type 1 diabetes or diabetic ketoacidosis - Contraindicated in patients with a history of medullary thyroid carcinoma or MEN2 - Monitor diabetic retinopathy in high-risk patients → Off-Label Considerations: - May delay progression from prediabetes to diabetes (observed in select studies) - Supports weight loss in OSA patients through metabolic improvement - Under investigation for long-term reduction in cancer risks related to obesity
Store unused pens in the refrigerator at 2–8°C. Do not freeze. Once in use, pens may be kept at room temperature (below 30°C) for up to 21 days. Keep protected from direct sunlight and moisture. Keep out of reach of children and pets.
Common side effects include nausea, vomiting, diarrhea, decreased appetite, and abdominal discomfort. These are typically dose-dependent and tend to subside with continued use. Less common adverse effects include injection site reactions, fatigue, and constipation. Serious but rare effects include pancreatitis, gallbladder disease, acute kidney injury (due to dehydration), and hypersensitivity reactions. Although not associated with high hypoglycemia risk when used alone, caution is required when combined with insulin or sulfonylureas. Any persistent or severe symptoms should prompt medical consultation.
Starting a new, important medication like Mounjaro comes with a lot of questions. I contacted their customer support before placing my order to ask about the cold-chain shipping process. The agent was patient, knowledgeable, and walked me through the entire procedure, from packing to delivery. This transparency and willingness to help was incredibly reassuring. The pen arrived exactly as described. This top-tier service is what makes them stand out.
The pen was securely packaged inside a cooled container. Very professional.
My first order was handled perfectly. The cold-chain shipping gives me confidence in the product's quality.
The ordering process was simple, and everything arrived as expected. Looking forward to the journey.
A positive start with a reliable pharmacy is the best way to begin a new treatment plan.
No combo deals available at the moment.
